CD4 and neoplasm: We recently developed a multi-peptide KRAS vaccine (KVax) that contains several long peptides with high affinity and binds to multiple MHC class II alleles;8 KVax is thus designed to promote KRAS-specific CD4+ T cell activation and infiltration to the tumor microenvironment which may facilitate tumor rejection8.